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Abstract 
The demand for sublingual tablets has been growing during the previous 
decades especially for drugs with extensive hepatic first-pass metabolism. 
Vinpocetine, a widely used neurotropic agent, has low oral bioavailability due to 
its poor aqueous solubility and marked first-pass metabolism. Accordingly, the 
aim of this work was to develop tablets for the sublingual delivery of 
vinpocetine. Initially, the feasibility of improving vinpocetine’s poor aqueous 
solubility by preparing kneaded solid systems of the drug with β-Cyclodextrin 
and hydroxy acids (citric acid and tartaric acid) was assessed. The solid system 
with improved solubility and dissolution properties was incorporated into porous 
tablets that rapidly disintegrate permitting fast release of vinpocetine into the 
sublingual cavity. The pores were induced into these tablets by directly 
compressing the tablets’ excipients with a sublimable material, either camphor 
or menthol, which was eventually sublimated leaving pores. The obtained 
results demonstrated that the tablets prepared using camphor attained sufficient 
mechanical strength for practical use together with rapid disintegration and 
dissolution.  In vivo absorption study performed in rabbits indicated that the 
sublingual administration of the proposed porous tablets containing vinpocetine 
solid system with β-Cyclodextrin and tartaric acid could be useful for therapeutic 
application. 364  M. H. Aburahma et al.:  
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Introduction 
Vinpocetine, a poorly-water soluble base type drug, is widely used for treatment of 
disorders arising from cerebrovascular and cerebral degenerative diseases [1]. It is 
reported to increase the cerebral blood flow to ischemic areas in patients with 
cerebrovascular disease, to decrease platelet aggregability in patients with transient 
ischemic attack, and to increase red cells deformability in stroke patients [1]. Although 
vinpocetine shows considerable therapeutic effects, its usefulness is limited by its very 
poor bioavailability (~7%) [2] owing to its poor aqueous solubility [3] and manifested 
hepatic first-pass metabolism [4]. Consequently, it is highly desirable to incorporate 
vinpocetine in a formulation that overcome both difficulties leading to higher degree of 
bioavailability. 
Systemic drug delivery through sublingual mucosa is one of the best known methods to 
bypass hepatic first-pass metabolism as drugs are not exposed to the metabolic enzymes 
of the liver [5]. On contact with the sublingual mucosa, the drug permeates across the 
mucosal tissue to reach the systemic circulation directly. An important factor that precedes 
permeation of drug is its solubilization in aqueous saliva [6]. Vinpocetine may be 
considered as a suitable candidate for sublingual delivery due to its small dose (5 mg), 
appropriate partition coefficient (log Ko/w = 3.56), and moderate molecular weight (350.46) 
[7]. However, its sublingual delivery may be extremely challenging due to its poor aqueous 
solubility.  
Cyclodextrins are a group of cyclic oligosaccharides that have been successfully employed 
in sublingual formulations to improve the solubility and bioavailability of various poorly 
soluble drugs [8, 9]. For a series of reasons; price, availability, good safety profile, and 
ability to mask drugs bitter taste [10]; β-Cyclodextrin (βCD) was selected in this study. 
Moreover, several studies have demonstrated the effectiveness of incorporating hydroxy 
acids with βCD in order to improve the aqueous solubility of poorly-water soluble basic 
drugs [11, 12]. Therefore, it seemed of great interest to investigate the effect of adding 
either citric acid or tartaric acid with βCD on the solubility and dissolution of vinpocetine. 
These two hydroxy acids were chosen due to their sour palatable taste upon dissolution in 
the sublingual cavity. 
Nevertheless, sublingual delivery systems are compromised by the possibility of the 
patient swallowing the active substance before it has been released and absorbed locally 
into the systemic circulation [13]. Hence, this paper introduces a porous tablet system that 
assures rapid disintegration and release of vinpocetine after its sublingual administration. 
Porous structure was induced into these tablets by sublimation of either menthol or 
camphor which was directly compressed with the tablets excipients [14–16].  
To the best of our knowledge, up to date, no report has ever dealt with the sublingual 
delivery of vinpocetine, althought this is highly beneficial from theraputic view point. 
Accordingly, the objective of this study was to prepare and characterize porous sublingual   Sublingual Porous Tablets Containing Vinpocetine  365 
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tablets of vinpocetine. These tablets contained ternary kneaded solid system of 
vinpocetine with βCD and hydroxy acid that is characterized by maximum solubility and 
dissolution. Pores that assures rapid disintegration of the tablets in the sublingual cavity 
were induced into the proposed tablets using sublimable materials. The pharmaco-
technical properties, namely weight variation, hardness, friability, content uniformity, 
wetting time, in vitro and oral disintegration time, and in vitro dissolution were evaluated for 
the prepared tablets. Finally, the relative bioavailability of the optimal porous tablets 
formulation was compared to the commercially available Cavinton
® tablets in fasted rabbits 
using cross over design. 
Results and Discussion 
In vitro dissolution studies  
The in vitro dissolution profiles of vinpocetine from the investigated physical mixtures and 
kneaded solid systems are illustrated in Figure 1.  
 
Fig. 1.   In vitro dissolution profiles of vinpocetine (n=3) from its binary and ternary solid 
systems with β-cyclodextrin and hydroxy acids performed in phosphate buffer of 
pH 6.8 at 37±0.5°C. (a) Physical mixtures (b) Kneaded solid systems.(Vin: 
Vinpocetine; Cit: Citric acid; Tar: Tartaric acid). 366  M. H. Aburahma et al.:  
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It is clear that binary and ternary physical mixtures exhibited higher extents of vinpocetine 
dissolution compared to that of pure vinpocetine, which showed negligible dissolution. This 
finding agrees well with that mentioned by Ribeiro et al. [17] who attributed this 
improvement in drug dissolution to the solubilization action of βCD and hydroxy acids 
operating locally in the aqueous hydrodynamic layer surrounding the drug particles.  
Moreover, the kneaded solid systems showed better extents of vinpocetine dissolution 
compared to their respective physical mixtures probably due to the increase in drug-carrier 
contact surface as a consequence of the more drastic mechanical treatment imposed 
during the kneading process as reported in literature [17–20]. Furthermore, the extent of 
vinpocetine dissolution from its ternary kneaded solid systems was higher than those of 
the binary kneaded solid systems. This observation may be related to the existence of 
hydroxy acids which probably created an acidic microenvironment pH more favourable for 
drug dissolution. Also, it is reported that the hydroxy acids act as a bridge between the 
drug molecules and βCD molecules by interacting with the basic functional groups of the 
drug and hydroxyl groups of βCD [21].  
It is worth noting that the type of hydroxy acid used had a noticeable effect on vinpocetine 
dissolution profiles from ternary kneaded solid systems where the latter, prepared with 
tartaric acid, showed higher extents of drug dissolution than those prepared with citric acid. 
This might be reasonably attributed to the suitable conformation and the better steric fit 
that tartaric acid provides for vinpocetine with βCD which consequently led to an increase 
in the solid system solubility and dissolution. Similar outcome was reported previously in 
literature [22].  
Tab. 1.   Aqueous solubility (mg/ml ±SD, n=3) at 25°C, relative increment, and 
dissolution efficiency of vinpocetine from the prepared solid systems.(Vin: 
Vinpocetine; Tar: Tartaric acid; Cit: Citric acid). 
Physical mixtures  Kneading solid systems 
Composition  Solubility 
mg/ml± SD R.I.
a D.E.






c  0.02 ± 0.01  2.8  6.18  0.21 ± 0.08 26.7  15.19 
Vin:βCD:Tar 
(1:2:1)
c  2.87 ± 0.1  359.0  13.86  5.64 ± 0.6  705.6  56.51 
Vin:βCD:Cit 
(1:2:1)
c  2.46 ± 0.4  307.6  12.27  3.93 ± 0.3  491.8  22.00 
Vin:βCD:Tar 
(1:2:2)
c  3.45 ± 0.2  431.2  16.71  7.30 ± 0.8  913.2  90.30 
Vin:βCD:Cit 
(1:2:2)
c  2.92 ± 0.3  364.8  14.32  4.09 ± 0.4  512.2  34.42 
a Relative Increment (R.I.) = ratio between drug solubility in the prepared solid 
system to that of drug alone. 
b Dissolution Efficiency (D.E.)= calculated from the area under the dissolution curve 
at 60 minutes. 
c The values between brackets represent the molar ratio of vinpocetine: βCD: 
hydroxy acid. 
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Solubility studies 
Table 1 compiles the solubility, relative increment, and dissolution efficiency data of the 
prepared binary and ternary physical mixtures and kneaded solid systems. As observed, 
the aqueous solubility of vinpocetine (0.008 mg/ml at 25°C) increased in all of the prepared 
binary and ternary physical mixtures and kneaded solid systems. The latter was clearly 
more soluble than their corresponding physical mixtures and this was related to the 
increase in the interaction between the drug and βCD as a consequence of the more 
drastic mechanical treatment during kneading process compared to physical mixing [19].  
Moreover, kneaded ternary solid systems were clearly more effective in enhancing 
vinpocetine solubility than the kneaded binary solid systems. This is probably attributed to 
the presence of hydroxy acids that gave a synergistic mutual solubility enhancing effect to 
both vinpocetine and βCD. It is reported that the hydroxyl groups present in hydroxy acids 
interact with βCD through hydrogen bonds formation and/or modify the hydrogen bonds 
network of the surrounding water molecules leading to increase in βCD solubility [11]. 
Preparation of porous tablets containing vinpocetine 
The following additives were selected to prepare vinpocetine porous tablets. Mannitol was 
employed as a diluent as it has negative heat of solution which imparts a unique cooling 
sensation and pleasant taste when used in formulations for tablets intended to dissolve in 
the oral cavity [23]. Ac-Di-Sol was used as a super disintegrant as it has fibrous particles 
that acts as channels to absorb water allowing rapid disintegration [24]. Camphor and 
menthol were chosen as sublimable materials, to induce pores into the compressed 
tablets, as they have the ability to sublimate (i.e., transit from solid phase directly to vapor 
phase without passing through an intermediate liquid phase). Kollidon CL was included in 
the formulations as a bioadhesive component in order to increase the contact time of 
vinpocetine at the sublingual mucosa, thereby reduce the potential intra/inter-individual 
variability resulting from swallowing the drug [13,  25]. Nevertheless, it is reported that 
Kollidon CL does not interfere with the rapid disintegration of the tablets [26]. Magnesium 
stearate was selected as a lubricant owing to its superior lubrication properties. However, 
its highly hydrophobic nature might build a barrier against rapid disintegration and 
dissolution of tablets. Accordingly, only 0.25% of magnesium stearate was used as a 
lubricant for attaining good lubrication without interfering with rapid drug disintegration and 
dissolution.  
Morphological examination of the prepared porous tablets  
 
Fig. 2.   Photographs of (a) Directly compressed vinpocetine tablet containing 10% of 
camphor before sublimation. (b) Top view, (c) Cross section, and (d) Magnified 
surface view after removal from vacuum oven. 368  M. H. Aburahma et al.:  
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The morphology of the tablets was examined using an optical microscope and selected 
photographs are illustrated in figures 2, 3, and 4. It is evident that the sublimation of either 
menthol or camphor caused a remarkable change in the outer surface of the tablets 
manifested as pores and cavities. The latter increased in count by the increase in camphor 
content from 10% to 20% as shown in figures 2b and 3b. Furthermore, those tablets 
prepared using 10% of menthol showed surface fines and cracks on the tablets surface 
after sublimation of menthol as depicted in figures 4b and 4c. 
 
Fig. 3.   Photographs of (a) Directly compressed vinpocetine tablet containing 20% of 
camphor before sublimation. (b) Top view, (c) Cross section, and (d) Magnified 
surface view after removal from vacuum oven. 
 
Fig. 4.   Photographs of (a) Directly compressed vinpocetine tablet containing 10% of 
menthol before sublimation. (b) Top view, and (c) Side view after removal from 
vacuum oven. 
Characterization of the prepared porous tablets containing vinpocetine 
Table 2 represents a compilation of the average weight, hardness, and friability of the 
prepared tablets containing vinpocetine. It was observed that a decrease in the weight of 
tablets occurred after their removal from vacuum oven. This decrease corresponded to the 
weight of sublimable materials added which indicates that all of the sublimable material, 
either camphor or menthol, has been sublimated from the compressed tablets [14].  
It was noticed that, all of the prepared tablets of different formulations showed acceptable 
physical performance regarding tablets’ intactness except those containing 20% of 
menthol, namely F5 and F10, which were crushed during their removal from vacuum oven 
and hence were excluded from further study. The hardness of the tablets was decreased 
after sublimation of the sublimable materials present in them. This was credited to the 
increase in tablets porosity which consequently decreased tablets’ hardness. The friability 
values of tablets belonging to formulations F1, F2, F3, F6, F7 and F8 complied with the 
limits set by the British Pharmacopoeia [27]. Tablets prepared using 20% of camphor, 
namely F3 and F8, exhibited higher percentage of friability than their counterparts 
prepared using 10% of camphor, namely F2 and F7. This may be attributed to the   Sublingual Porous Tablets Containing Vinpocetine  369 
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presence of more pores in the first than the second. This finding is in agreement with that 
mentioned by Bi et al. [28] that porosity contributes negatively on tablets’ friability. On the 
other hand, tablets belonging to formulations F4 and F9 prepared using 10% of menthol 
were very friable and didn’t comply with the pharmacopoeial limits [27] after sublimation of 
menthol. This observation might be attributed to the minute particles of menthol employed 
in these tablets which left numerous small pores after sublimation [14]. Hence, these 
tablets formulations were excluded from further studies. 
Tab. 2.   Average weight, hardness, and friability of the prepared tablets. 
Formulation  Average weight
a 
(mg ± SD) 
Average weight
b
(mg ± SD) 
Hardness
a
(Kg ± SD) 
Hardness
b 
(Kg ± SD) 
Friability
(%) 
F1  200.09 ± 0.09  199.97 ± 0.04  6.96 ± 0.28  7.18 ± 0.17  0.13 
F2  200.04 ± 1.02  180.07 ± 1.26  7.11 ± 0.13  5.28 ± 0.21  0.32 
F3  199.94 ± 0.08  161.20 ± 1.27  7.01 ± 0.32  4.13 ± 0.43  0.65 
F4  198.06 ± 1.12  183.40 ± 2.54  6.87 ± 0.45  1.71 ± 0.38  2.95 
F5  200.03 ± 1.08  Undetermined* 
F6  200.10 ± 1.34  198.70 ± 1.27  6.11 ± 0.15  6.17 ± 0.31  0.16 
F7  199.94 ± 1.10  181.20 ± 1.08  5.93 ± 0.53  4.23 ± 0.28  0.42 
F8  200.01 ± 1.07  158.90 ± 0.57  5.89 ± 0.07  3.64 ± 0.21  0.72 
F9  199.97 ± 1.21  184.81 ± 2.71  5.87 ± 0.42  0.98 ± 0.42  2.73 
F10  199.95 ± 0.08  Undetermined* 
aBefore sublimation; 
b After sublimation; * The tablets were broken after sublimation of 20% of menthol in 
vacuum oven. 
 
Table 3 compiles the average vinpocetine content, wetting time, in vitro and oral 
disintegration time of selected sublingual tablets. It is obvious that the drug content of all 
the investigated tablets complied with the pharmacopoeial specifications. It was found that 
tablets belonging to formulation F3 prepared using 20% of camphor exhibited shorter 
wetting time and disintegration time (in vitro and oral) than F2 prepared using 10% of 
camphor. This could be attributed to the greater number of pores formed in these com-
pressed tablets which resulted from the sublimation of the higher percentage of camphor.  
Tab. 3.   Average drug content, wetting time, in vitro disintegration time, and oral 
disintegration time of the prepared tablets. 










F1  98.05 ± 0.84  > 300  785.30 ± 16.08  447.42 ± 12.47 
F2  95.49 ± 0.62  95.46  135.20 ±   8.24    63.49 ±   4.15 
F3  93.82 ± 0.44  68.28    98.74 ±   4.21   54.12  ±   2.87 
F6  94.53 ± 0.66  65.91    94.61 ±   6.18   47.45  ±   3.18 
F7  94.07 ± 0.91  53.20    58.18 ±   5.23   38.93  ±   5.72 
F8  97.18 ± 0.57  40.45    34.51 ±   3.47   23.21  ±   2.24 
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Moreover, it was evident that tablets containing Ac-Di-Sol together with pores that were 
formed after sublimation of camphor, namely F7 and F8, possessed the least wetting time 
and disintegration time. This might be attributed to the synergistic effect of Ac-Di-Sol as a 
super disintegrant with the pores caused by camphor sublimation. All of the tested tablets 
belonging to different formulations were subjected to in vitro dissolution testing except F1 
as it showed the longest disintegration and wetting time.  
In vitro dissolution of vinpocetine sublingual tablets 
The saliva ordinary maintains the pH of the mouth between 5.6 and 7.8 [13]. Furthermore, 
literatures performed dissolution studies on sublingual tablets in phosphate buffer of pH 
6.8 [8, 9]. Therefore, phosphate buffer of pH 6.8 was indicated as a dissolution medium in 
dissolution studies. 
 
Fig. 5.   Dissolution profile of vinpocetine (n = 3) from the prepared porous sublingual 
tablets performed in phosphate buffer of pH 6.8 at 37±0.5°C.  
Figure 5 illustrates the dissolution profile of vinpocetine from the prepared porous 
sublingual tablets. It is obvious that, porous tablets prepared according to the formulation 
F8 exhibited the highest extent of drug dissolution compared with the other tested tablets 
of different formulations. This finding might be attributed to the greater number of pores 
present in these tablets due to sublimation of 20% of camphor in addition to the existence 
of 5% of Ac-Di-Sol in them resulting in higher rate of tablets disintegration and dissolution. 
Therefore, this sublingual tablets formulation was subjected to further investigations 
implicating an in vivo absorption study. 
In vivo evaluation of the porous sublingual tablets 
The plasma profiles of vinpocetine in twelve rabbits following oral administration of 
Cavinton
® tablets and sublingual administration of the sublingual porous tablets belonging 
to formulation F8 are represented in figure 6 and the corresponding pharmacokinetic 
parameters are collectively presented in table 4.    Sublingual Porous Tablets Containing Vinpocetine  371 
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Tab. 4.   Summary of pharmacokinetic parameters of vinpocetine following the adminis-
tration of Cavinton
® tablets and sublingual porous tablets of formulation F8. 
Parameter Cavinton
® tablets  Sublingual porous tablets (F8) 
Cpmax (μg.ml
−1)
a  0.26 ± 0.04  1.34 ± 0.63 
Tmax (hour)
a  1.41 ± 0.80  1.08 ± 0.20 
AUC(0-t) (μg.hr.ml
−1)
a  0.82 ± 0.04  2.53 ± 0.40 
% Relative bioavailability  – 306.69% 
aMean± Standard deviation. 
 
 
Fig. 6.   Mean plasma concentrations of vinpocetine (mean ±SD, n = 12) following oral 
administration of Cavinton
® tablets and the sublingual administration of porous 
tablets belonging to formulation F8. 
Taking Cavinton
® tablets as the reference product, the relative bioavailability of 
vinpocetine after sublingual administration of the selected sublingual tablets, containing 
vinpocetine kneaded solid system with βCD and tartaric acid in 1:2:2 molar ratio, 
respectively, was 306.69. This increase in vinpocetine’s bioavailability after sublingual 
administration is most probably due to the avoidance of its first-pass metabolism. 
Moreover, it is reported that βCD present in the incorporated kneaded product have the 
ability to interact with the macromolecules of sublingual membrane causing marked 
improvement in the drug sublingual absorption [29]. 
Paired t test was performed in order to statistically analyze the difference between the 
pharmacokinetic parameters of the investigated sublingual tablets and Cavinton
® tablets. It 
was found that there were significant differences in Cpmax and AUC(0-10) between 
Cavinton
® tablets and the tested sublingual tablets. However, a decrease in the Tmax was 
observed in case of the sublingual tablets compared to the conventional commercial 
tablets. This difference was found to be statistically non significant. 
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Conclusion 
The present study was carried out to develop porous tablets for sublingual administration 
of vinpocetine. The major obstacle against sublingual delivery of vinpocetine was its low 
aqueous solubility, which was overcome by kneading the drug with βCD and tartaric acid 
in a simple and easy-to-scale-up formulation strategy. Porous structure, aiding rapid 
disintegration and dissolution of tablets in the sublingual cavity, was successfully achieved 
after camphor sublimation from the directly compressed tablets by means of vacuum oven. 
Therefore, it is reasonable to say the adopted formulation strategy to prepare porous 




Vinpocetine was provided by Medical Union Pharmaceuticals Co. (Abu Sultan, Egypt). β-
cyclodextrin (MW 1135), camphor, and menthol were purchased from Sigma Chemical 
Company (St. Louis, USA). Citric acid and tartaric acids were obtained from El-Nasr 
pharmaceutical Co. (Abu Zaabal, Egypt). Mannitol was donated by Roquette Corp. 
(Lesterm, France). Kollidon CL (cross-linked polyvinylpyrrolidone) was purchased from 
BASF corp. (Ludwigshafen, Germany). Ac-Di-Sol (crosscarmellose sodium) was purchase 
from FMC Corp. (Philadelphia, USA). Magnesium stearate was obtained from Prolabo 
(Paris, France). Cavinton
® tablets (5 mg vinpocetine) were purchased from ACAPI (Badr 
City, Egypt). HPLC grade methanol and acetonitrile were obtained from Romil Limited 
(London, United Kingdom). All other reagents used were of analytical grade and were 
used as received. 
Methods 
Preparation of vinpocetine-βCD binary and ternary solid systems 
With the aim of improving the poor aqueous solubility and dissolution of vinpocetine; binary 
solid systems of vinpocetine with βCD in 1:2 molar ratios, and ternary solid systems with 
βCD and hydroxy acids (tartaric or citric acid) in 1:2:1 and 1:2:2 molar ratios were 
prepared by kneading method. These components in their adequate molar ratios were 
mixed together followed by kneading them thoroughly with the least amount of water for 20 
minutes in a glass mortar. The formed homogenous mixture was left to dry for 48 hours in 
a desiccator maintained at room temperature. The corresponding physical mixtures were 
prepared in the same molar ratios as in the prepared kneaded solid systems for 
comparative purpose. 
In vitro dissolution testing 
Preliminary dissolution tests, aimed at selecting the solid system with superior dissolution 
properties, were performed according to the dispersed amount method [30]. Binary and 
ternary physical mixtures and their corresponding kneaded solid systems equivalent to five 
milligrams of vinpocetine were prepared and were added to 100 ml of phosphate buffer of 
pH 6.8, thermostated at 37±0.5°C, in a 200 ml beaker. A magnet was immersed in the 
beaker and rotated at 50 rpm. At appropriate time intervals, samples from the dissolution 
medium were withdrawn, filtered through Millipore filter of 0.45 μm pore size, and   Sublingual Porous Tablets Containing Vinpocetine  373 
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spectrophotometrically assayed at λmax 314.4 nm for drug content. The removed samples 
were replenished with equal volumes of dissolution medium to keep the dissolution 
medium volume constant. The dissolution efficiency of vinpocetine from the prepared solid 
systems, after 60 minutes, was calculated according to Khan [31]. 
Solubility studies 
Solubility studies were performed by adding excess of vinpocetine, binary and ternary 
kneaded solid systems, and their corresponding physical mixtures to 10 ml distilled water 
in glass vials and were shaken in a thermostatically controlled shaking water bath main-
tained at 25±0.5°C. After 48 hours, aliquots were withdrawn from vials, filtered through 
0.45μm Millipore filter, and spectrophotometrically measured for estimating drug content. 
Preparation of porous tablets containing vinpocetine 
Vinpocetine tablets were prepared by direct compression technique according to the 
compositions presented in Table 5.  















up to (mg) 
F1  41.66       200 
F2  41.66 10      200 
F3  41.66 20      200 
F4  41.66  10   200 
F5  41.66  20   200 
F6  41.66     5  200 
F7  41.66 10    5  200 
F8  41.66 20    5  200 
F9  41.66  10  5  200 
F10  41.66  20  5  200 
a All batches contained 2% Kollidon CL as a bioadhesive agent, and 0.25% magnesium stearate 
as a lubricant. 
b Vinpocetine: βCD: tartaric acid kneaded solid system in 1:2:2 molar ratios equivalent to 5 mg 
vinpocetine. 
 
Vinpocetine:  βCD: tartaric acid kneaded solid system prepared in 1:2:2 molar ratios, 
respectively, that showed the highest solubility and extent of drug dissolution was 
incorporated in the proposed porous sublingual tablets. It was mixed with Kollidon CL for 
20 minutes using a pestle in a glass morter. Following that, the calculated amount of 
mannitol was added to the above mixture and blended together for additional ten minutes. 
Prior to compression, the sublimable material, either camphor or menthol, was added to 
the tablets mixture and was mixed with for 20 minutes. Lastly, magnesium stearate was 
incorporated to the previous mixture and mixed for additional 10 minutes. Tablets of 200 
mg were prepared using a single punch tablet press machine equipped with 8 mm punch 
and die. The tablets were then placed in a vacuum oven adjusted at 60°C for 2 hour to 374  M. H. Aburahma et al.:  
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eliminate camphor or menthol by sublimation leaving many pores where they previously 
existed in the compressed tablets [14]. The formed pores or cavities allow rapid penetrat-
ion of saliva into these tablets leading to fast disintegration when placed in the oral cavity. 
Morphological examination of the prepared tablets 
The morphological characteristics of the tablets after sublimation of the contained 
sublimable materials in the vacuum oven were examined using an optical microscope.  
Physical characterization of the prepared tablets  
The mean weight of twenty tablets, randomly selected from each formulation, was 
determined. Following that, the tablets were placed in a vacuum oven at 60°C for 2 hours 
to remove camphor or menthol by sublimation and the tablets were reweighed to deduce 
the weight loss [16]. Moreover, the mean hardness of ten tablets, selected from each 
formulation, before and after introducing into the vacuum oven, was evaluated and 
expressed in Kilograms. Added to that, the friability of the tablets, after removal from the 
vacuum oven, was performed according to British Pharmacopoeia [27]. It should be noted 
here that tablets which passed the pharmacopoeial demands relevant to weight variation, 
hardness, and friability tests were subjected to the subsequent tests.  
Wetting time test 
The wetting time of the prepared tablets was measured using a simple procedure. In this 
method, a filter paper of 10 cm diameter was placed in a petri dish, with diameter of 10 cm, 
followed by addition of ten milliliters of water containing methylene blue. A tablet from each 
formulation was carefully placed on the surface of the filter paper. The time required for 
water to reach the upper surface of the tablets was recorded and taken as the wetting 
time. To check for reproducibility, these measurements were carried out in triplicates and 
the mean values were calculated [15].  
Disintegration time test 
The in vitro disintegration time of six tablets from each formulation was determined using 
USP disintegration tester [27]. However, for measuring the oral disintegration time of the 
prepared tablets, time needed for a tablet to completely disintegrate in subject’s mouth, 
three healthy volunteers were asked to rinse their mouths with distilled water. A tablet was 
placed below the tongue of each volunteer and immediately a stop watch was started. 
Then, the volunteers were allowed to move the tablets against the lower palate of the 
mouth with the base of their tongue and to cause a gentle tumbling action on the tablets 
without biting on them or turning them from one side to other. Immediately, after the last 
noticeable granules had disintegrated, the stop watch was stopped and the recorded time 
was taken as the oral disintegration time [32]. 
Content uniformity 
The uniformity of vinpocetine content in different tablets was determined by crushing ten 
tablets from each formulation and determining the content of each tablet individually [27]. 
The weight of each tablet was dissolved in 100 ml of 0.1N HCl. The solution was then 
filtered, properly diluted and the absorbance was spectrophotometrically measured at 
314.8 nm and then vinpocetine content of each tablet was calculated.   Sublingual Porous Tablets Containing Vinpocetine  375 
Sci Pharm. 2010; 78: 363–379. 
In vitro dissolution of vinpocetine sublingual tablets  
The dissolution of vinpocetine from its tablets was performed in 200 ml phosphate buffer of 
pH 6.8, maintained at a temperature of 37±0.5°C, using the USP Dissolution Tester, 
Apparatus I, at rotation speed of 50 rpm. The dissolution test was done by placing a tablet 
from each formulation, containing vinpocetine kneaded solid system equivalent to 5mg 
vinpocetine, in the dissolution basket. Aliquots from the dissolution medium were 
withdrawn at selected time intervals, filtered through Millipore filter membrane of 0.45 μm 
pore size, and analyzed for vinpocetine content by measuring their absorbances at 314.4 
nm. All the withdrawn samples were replenished with equal volumes of phosphate buffer 
of pH 6.8 to keep the dissolution volume constant. 
In vivo evaluation of the prepared porous sublingual tablets 
Twelve healthy male albino rabbits (2–2.3 kg) were purchased from the laboratory animal 
center of faculty of Pharmacy (Cairo University, Egypt). The rabbit was selected as an 
animal model for absorption studies due to its convenient size, which allows for sublingual 
administration and blood sample volumes that are sufficient for quantitative analysis. In 
addition, rabbits have been described as one of the few laboratory animals that do not 
have keratinized mucosa, thus closely resembling human sublingual mucosal tissue 
[5, 33].  
The rabbits were divided into two groups, each composed of six rabbits. The study was 
conducted in a cross-over manner with a wash out period of one week. All of the rabbits 
were healthy during the period of the experiment. The rabbits were fasted overnight but 
had free access to water. The investigated sublingual porous tablets were administrated 
using the same procedures adopted by Mannila et al. [8, 9]. Whereby the rabbits were 
anaesthetized and positioned on a table with the lower jaw supported in a horizontal 
position. Rabbits’ tongues were carefully lifted with tweezers and the selected sublingual 
tablet containing vinpocetine complex was placed carefully under the tongue. The rabbits 
were kept anaesthetized for at least three hours to ensure the maintenance of the tablet in 
the sublingual cavity without escaping down the GI tract. Cavinton
® tablets were also orally 
administered to the rabbits by tube feeding with the aim of comparing the bioavailability of 
sublingual tablets to that of oral tablets.  
The blood samples (3 ml) were withdrawn via the marginal ear vein into heparinized tubes 
at specified time intervals and the plasma was separated immediately by centrifugation at 
3000 rpm for 10 min followed by storing at −20°C until being assayed for vinpocetine 
content. The concentration of vinpocetine in rabbit's plasma samples was determined 
using the HPLC procedures reported by the Abd Elbary et al. [34]. 
Pharmacokinetic data analysis and bioavailability evaluation 
The maximal plasma concentration (Cmax) and the time to reach maximum plasma 
concentration (Tmax) were directly obtained from the plasma data and were compared for 
statistical significance by Paired t test. The area under the plasma concentration-curve 
(AUC0-10) was also calculated using the trapezoidal rule and the bioavailability of the 
investigated sublingual tablets to Cavinton
® tablets was calculated.  
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